Evidence map›Paper›PMID 26824949›Full record

ArticleAntimicrobial agents and chemotherapy2016

A Complex Network of Interactions between S282 and G283 of Hepatitis C Virus Nonstructural Protein 5B and the Template Strand Affects Susceptibility to Sofosbuvir and Ribavirin.

Anupriya S Kulkarni, Masad J Damha, Raymond F Schinazi, Hongmei Mo, Brian Doehle, Selena M Sagan, Matthias Götte

Open access · bronzeAbstract read
In one paragraph

Article in Antimicrobial agents and chemotherapy, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
1.2field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 12 citations in OpenAlex.

  1. Trial
  2. Article
  3. Review
  4. Article
  5. Article
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 4 institutions in 2 countries.

Anupriya S KulkarniDepartment of Microbiology and Immunology, McGill University, Montreal, Quebec, Canada.
Masad J DamhaDepartment of Chemistry, McGill University, Montreal, Quebec, Canada.
Raymond F SchinaziCenter for AIDS Research, Laboratory of Biochemical Pharmacology, Department of Pediatrics, Emory University School of Medicine and Veterans Affairs Medical Center, Atlanta, Georgia, USA.
Hongmei MoGilead Sciences, Inc., Foster City, California, USA.
Brian DoehleGilead Sciences, Inc., Foster City, California, USA.
Selena M SaganDepartment of Microbiology and Immunology, McGill University, Montreal, Quebec, Canada.
Matthias GötteDepartment of Microbiology and Immunology, McGill University, Montreal, Quebec, Canada Department of Biochemistry, McGill University, Montreal, Quebec, Canada Department of Medical Microbiology and Immunology, University of Alberta, Edmonton, Alberta, Canada gotte@ualberta.ca.
McGill University · CAGilead Sciences (United States) · USJohns Hopkins University Center for AIDS ResearchUniversity of Alberta · CA

Funding

Virology and Molecular Biomarkers CoreP30AI050409 · NIAID · EMORY UNIVERSITY · PI Ann M Chahroudi, Colleen F Kelley · 2002 to 2026
$74.0M
CIHRNIAID NIH HHS 2P30AI050409NIAID NIH HHS P30 AI050409
6 · The paper itself

Abstract

The hepatitis C virus (HCV) RNA-dependent RNA-polymerase NS5B is essentially required for viral replication and serves as a prominent drug target. Sofosbuvir is a prodrug of a nucleotide analog that interacts selectively with NS5B and has been approved for HCV treatment in combination with ribavirin. Although the emergence of resistance to sofosbuvir is rarely seen in the clinic, the S282T mutation was shown to decrease susceptibility to this drug. S282T was also shown to confer hypersusceptibility to ribavirin, which is of potential clinical benefit. Here we devised a biochemical approach to elucidate the underlying mechanisms. Recent crystallographic data revealed a hydrogen bond between S282 and the 2'-hydroxyl of the bound nucleotide, while the adjacent G283 forms a hydrogen bond with the 2'-hydroxyl of the residue of the template that base pairs with the nucleotide substrate. We show that DNA-like modifications of the template that disrupt hydrogen bonding with G283 cause enzyme pausing with natural nucleotides. However, the specifically introduced DNA residue of the template reestablishes binding and incorporation of sofosbuvir in the context of S282T. Moreover, the DNA-like modifications of the template prevent the incorporation of ribavirin in the context of the wild-type enzyme, whereas the S282T mutant enables the binding and incorporation of ribavirin under the same conditions. Together, these findings provide strong evidence to show that susceptibility to sofosbuvir and ribavirin depends crucially on a network of interdependent hydrogen bonds that involve the adjacent residues S282 and G283 and their interactions with the incoming nucleotide and complementary template residue, respectively.

Indexed as

Antiviral AgentsBase SequenceBinding SitesCloning, MolecularEscherichia coliGene ExpressionHepacivirusHydrogen BondingMicrobial Sensitivity TestsMutationProtein BindingRecombinant ProteinsRibavirinRNA-Dependent RNA PolymeraseRNA, ViralSofosbuvirAntiviral AgentsNS-5 protein, hepatitis C virusRecombinant ProteinsRibavirinRNA-Dependent RNA PolymeraseRNA, ViralSofosbuvirViral Nonstructural Proteins

Identifiers

PMID26824949
PMCPMC4808174
OpenAlexW2326333490

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.